A panel of experts on the subject recommended the drug regulator to authorize the use of emergency services (EUA) in Russia’s single-dose regimen Sputnik Light, sources said on Friday.
Sputnik Light was developed by Russia’s Gamaleya Center, located on an adenovirus vector platform. In October last year, the government approved the export of Sputnik Light, which is manufactured in India by Hetero Biopharma Limited.
Sputnik is similar to part 1 of the Russian Sputnik V vaccine used in India vaccine strikes. India donated about 12 doses of Sputnik V during the adult vaccination campaign.
Earlier the company had stated that a single shot vaccine had shown 70 percent effectiveness in combating infection with Delta variation .
“First Gamaleya Center study found Sputnik Light significantly increases antibodies against Omicron based on sera 2-3 months after the 100% rehabilitation of Sputnik Light as a stimulant made by the immune system to work against these alternatives, “Russian Direct Investment Fund he had said before.